Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.57 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742277 | 1.00 | MAPT (0.66) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL4048121 | 0.98 | MAPT (0.68) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL6741206 | 0.98 | MAPT (0.68) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL1189176 | 0.91 | SIGMAR1 (0.57) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL1190075 | 0.91 | SIGMAR1 (0.57) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL25154402 | 0.88 | MAPT (0.54) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL6927881 | 0.86 | OPRD1 (0.61) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL17069524 | 0.86 | MAPT (0.70) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL17426061 | 0.86 | MAPT (0.70) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL17426063 | 0.86 | MAPT (0.70) | MAPTSIGMAR1PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252694-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | RAYZEBIO, INC. | 2024-08-01 | — | — | US | disclosed |
| CN-118043042-A | Conjugate comprising a covalent binding agent for targeting intracellular KRAS G12C proteins | 瑞择生物公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11246949-B2 | Imaging contrast agents and uses thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-02-15 | — | — | US | disclosed |
| US-20140193344-A1 | IMAGING CONTRAST AGENTS AND USES THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2014-07-10 | — | — | US | disclosed |
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-6693190-B1 | TETRAAZACYCLODODECANE MACROCYCLE DERIVATIVES INCLUDING METAL COMPLEXES; MAGNETIC RESONANCE IMAGING AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2004-02-17 | — | — | US | disclosed |
| US-RE38329-E1 | Chelated complexes of paramagnetic metals with low toxicity | BRACCO IMAGING S.P.A. (IT) | 2003-11-25 | — | — | US | disclosed |
| EP-0872479-B1 | Chelated complexes of paramagnetic metals with low toxicity | BRACCO SPA (IT) | 2002-09-04 | — | — | EP | disclosed |
| US-6177562-B1 | Chelated complexes of paramagnetic metals with low toxicity | DIBRA S.P.A. (IT) | 2001-01-23 | — | — | US | disclosed |
| US-6149890-A | 12-CROWN-4-AMINE DERIVATIVE DIAGNOSTIC CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING | DIBRA S.P.A. (IT) | 2000-11-21 | — | — | US | disclosed |
| EP-0883610-B1 | PROCESS FOR PREPARING 1,4,7,10-TETRAAZACYCLODODECANE AND ITS DERIVATIVES | SCHERING AG (DE) | 2000-07-12 | — | — | EP | disclosed |
| EP-0872479-A1 | Chelated complexes of paramagnetic metals with low toxicity | BRACCO S.p.A. (IT) | 1998-10-21 | — | — | EP | disclosed |
| WO-1995031444-A1 | ENHANCED RELAXIVITY MONOMERIC AND MULTIMERIC COMPOUNDS | BRACCO INTERNATIONAL B.V. (NL) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252694-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | KRAS, NRAS, HRAS | MAPT 4078/4885SIGMAR1 4530/4885PDK1 4134/4885 |
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | H1-2, H1-0, H1-3 | MAPT 2852/4885SIGMAR1 1104/4885PDK1 3636/4885 |
| US-20140193344-A1 | IMAGING CONTRAST AGENTS AND USES THEREOF | SLC40A1, SLC39A14, SLC39A3 | MAPT 949/4885SIGMAR1 1046/4885PDK1 349/4885 |
| US-11246949-B2 | Imaging contrast agents and uses thereof | SLC40A1, SLC39A14, SLC39A3 | MAPT 949/4885SIGMAR1 1046/4885PDK1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.